Pricing Log in Create free account

Bolt Biotherapeutics, Inc. (BOLT) vs TScan Therapeutics, Inc. (TCRX)

Bolt Biotherapeutics, Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. Bolt Biotherapeutics, Inc. and TScan Therapeutics, Inc. are of similar size ($12.3M and $12.3M). Bolt Biotherapeutics, Inc. grew revenue faster over the last twelve months: 12.8% against 2.15%. Bolt Biotherapeutics, Inc. has the higher net margin (−611.5% vs −1,655.4%) and the higher return on invested capital (−143.8% vs −4,588.2%). Across the 17 metrics below, Bolt Biotherapeutics, Inc. leads on 12 and TScan Therapeutics, Inc. on 5.

Valuation

Metric BOLT TCRX Biotechnology median
P/E n/m n/m 10.60
P/S 2.35 3.29 9.40
P/B 0.87 0.34 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.37 0.66
EV/Sales 2.50 (6.19) 9.02
Earnings yield (252.15%) (505.56%) (32.88%)
Free cash flow yield (279.53%) (506.23%) (23.13%)

Profitability

Metric BOLT TCRX Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (654.53%) (1,695.15%) 0.00%
Net margin (611.47%) (1,655.35%) 0.00%
Free cash flow margin (655.72%) (1,665.18%) 0.00%
Return on equity (111.65%) (95.80%) (51.96%)
Return on assets (49.62%) (50.09%) (46.06%)
Return on invested capital (143.75%) (4,588.23%) 0.00%

Growth

Metric BOLT TCRX Biotechnology median
Revenue growth (TTM) 12.79% 2.15% 6.76%
EPS growth (last fiscal year) 45.91% 12.28% 29.88%
Revenue growth, 5-year CAGR 101.61% 56.92% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BOLT TCRX Biotechnology median
Debt to equity 1.47 0.47 0.00
Current ratio 2.61 3.37 4.97
Net debt to EBITDA 0.21 0.90 1.01

Dividend

Metric BOLT TCRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BOLT TCRX Biotechnology median
Market cap 12.29m 12.32m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack